An 8-Week Open-Label Trial of a 6-Day Course of Mifepristone for the Treatment of Psychotic Depression
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Several investigations suggest that mifepristone leads to the rapid amelioration of psychotic depression. However, these studies were of short duration (1 week or less) and included subjects who were taking other psychotropic medications. The goals of this study were to extend these findings by conducting an 8-week trial of mifepristone for subjects with psychotic depression who were taking no concomitant psychiatric medications. METHOD: Twenty subjects with a DSM-IV major depressive episode with psychotic features (for convenience we use the term psychotic depression) taking no psychotropic medications were given a 6-day course of mifepristone and followed as inpatients for a total of 8 weeks. Nonblinded ratings using the Hamilton Rating Scale for Depression (HAM-D) and Clinical Global Impressions scale (CGI) were performed at baseline and at the end of weeks 1, 4, and 8. The Brief Psychiatric Rating Scale (BPRS) was also administered at baseline and after weeks 4 and 8. Subjects were recruited between February 2003 and December 2003. RESULTS: Significant improvements in HAM-D and CGI scores were shown after 1 week and between weeks 1 and 4 but not between weeks 4 and 8. BPRS scores improved significantly after week 4, while the improvement in BPRS scores between weeks 4 and 8 was of borderline significance. CONCLUSION: Mifepristone appears to be a useful intervention for psychotic depression, leading to significant improvements even after a 1-week course of administration. Issues related to its optimal dosing and to prediction of response are discussed, as are the implications of lack of a placebo group and the use of nonblinded ratings in the present study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, depressive symptoms were considered secondary outcomes, and these trials often failed to show a significant improvement compared to placebo.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [94]
In the citing paper
“4 double-blind [89-92] and 2 open-label trials [93, 94] suggested a significant reduction in psychotic symptoms, which was the primary outcome of these trials.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [94]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
DST Studies in Psychotic Depression: A Meta-Analysis
Nelson, J. C., & Davis, J. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1497 · Cited by 356
An open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
A corticosteroid/dopamine hypothesis for psychotic depression and related states
Schatzberg, A. F., Rothschild, A. J., Langlais, P. J., Bird, E. D., & Cole, J. O. (1985) · Journal of Psychiatric Research · doi:10.1016/0022-3956(85)90068-8 · Cited by 244
Depression, Delusions, and Drug Response
(1975) · American Journal of Psychiatry · doi:10.1176/ajp.132.7.716 · Cited by 230
Successful Long-Term Treatment of Refractory Cushing's Disease with High-Dose Mifepristone (RU 486)
Chu, J. W. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3568 · Cited by 200
Cortisol Activity and Cognitive Changes in Psychotic Major Depression
Belanoff, J. K., Kalehzan, M., Sund, B., Fleming Ficek, S. K., & Schatzberg, A. F. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1612 · Cited by 181
Antiglucocorticoid treatment of depression: double-blind ketoconazole
Wolkowitz, O. M., Reus, V. I., Chan, T., Manfredi, F., Raum, W., Johnson, R., & Canick, J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00267-4 · Cited by 165
Cited by
Linking Molecules to Mood: New Insight Into the Biology of Depression
Krishnan, V., & Nestler, E. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.10030434 · Cited by 643
Mondelli, V., Cattaneo, A., Murri, M. B., Di Forti, M., Handley, R., Hepgul, N., Miorelli, A., Navari, S., Papadopoulos, A. S., Aitchison, K. J., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06745 · Cited by 303
Cortisol and depression: three questions for psychiatry
Herbert, J. (2013) · Psychological Medicine · doi:10.1017/s0033291712000955 · Cited by 301
“2006), others less dramatic results (Simpson et al. 2005).”
BackgroundGap Junction Dysfunction in the Prefrontal Cortex Induces Depressive-Like Behaviors in Rats
Sun, J.-D., Liu, Y., Yuan, Y.-H., Li, J., & Chen, N.-H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.319 · Cited by 258
Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300884 · Cited by 203
“This trend toward continuing amelioration of symptoms of psychosis beyond 8 days of treatment with mifepristone is consistent with recent published findings by Simpson et al (2005).”
Result
Metadata
- Authors
- Simpson, G. M., Sheshai, A. E., Loza, N., Kingsbury, S. J., Fayek, M., Rady, A., & Fawzy, W.
- Affiliations
- University of Southern California (US)
- ORCID
- Rady, Ahmed
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-05-15
- Volume
- 66
- Issue
- 05
- Pages
- 598-602
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2078916499
- Cited by
- 63
- References
- 23
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 3 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 1 · 2012: 7
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- mifepristone, psychotic depression, rapid-acting antidepressants, short-course treatment, antidepressant response, treatment response prediction, dosage
- MeSH terms
- Adolescent, Adult, Affective Disorders, Psychotic, Aged, Major Depressive Disorder, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Progesterone, Psychiatric Status Rating Scales, Receptors, Glucocorticoid, Mifepristone, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An 8-Week Open-Label Trial of a 6-Day Course of Mifepristone for the Treatment of Psychotic Depression. https://app.cochat.ai/papers/10.4088/jcp.v66n0509
- The paper
- Simpson, G. M., Sheshai, A. E., Loza, N., Kingsbury, S. J., Fayek, M., Rady, A., & Fawzy, W. (2005). An 8-Week Open-Label Trial of a 6-Day Course of Mifepristone for the Treatment of Psychotic Depression. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v66n0509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.